Bial Launches Education and Awareness Campaign for World Parkinson’s Day

Contributed by: Business Wire

Logo

Tags

Research

Nursing

Neurology

Clinical Trials

Biotechnology

Managed Care

Health

Pharmaceutical

Science

World Parkinson's Day

More Like This

Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s

Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s

PR Newswire associated0

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

Key Milestone in ACTIVATE Phase 2 Clinical Trial of BIA 28-6156

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025

Bial Launches KYNMOBI® (Apomorphine Hydrochloride) in the United Kingdom

Merz Therapeutics Presents New Research at World Parkinson Congress 2026, Revealing the Hidden Burden of "OFF" Episodes in Parkinson’s Disease